Anoikis related genes may be novel markers associated with prognosis for ovarian cancer.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Anoikis*/genetics ; Ovarian Neoplasms*/genetics; Humans ; Female ; Prognosis ; Nomograms ; Algorithms

The aim of this study was to determine the prognostic significance of anoikis related genes (ARGs) in ovarian cancer (OC) and to develop a prognostic signature based on ARG expression. We analyzed cohorts of OC patients and used nonnegative matrix factorization (NMF) for clustering. Single-sample gene-set enrichment analysis (ssGSEA) was employed to quantify immune infiltration. Survival analyses were performed using the Kaplan-Meier method, and differences in survival were determined using the log-rank test. The extent of anoikis modification was quantified using a risk score generated from ARG expression. The analysis of single-cell sequencing data was performed by the Tumor Immune Single Cell Hub (TISCH). Our analyses revealed two distinct patterns of anoikis modification. The risk score was used to evaluate the anoikis modification patterns in individual tumors. Three hub-genes were screened using the LASSO (Least Absolute Shrinkage and Selection Operator) method and patients were classified into different risk groups based on their individual score and the median score. The low-risk subtype was characterized by decreased expression of hub-genes and better overall survival. The risk score, along with patient age and gender, were considered to identify the prognostic signature, which was visualized using a nomogram. Our findings suggest that ARGs may play a novel role in the prognosis of OC. Based on ARG expression, we have developed a prognostic signature for OC that can aid in patient stratification and treatment decision-making. Further studies are needed to validate these results and to explore the underlying mechanisms.
(© 2024. The Author(s).)

Stat Med. 2013 Dec 30;32(30):5381-97. (PMID: 24027076)
Cell Death Dis. 2020 Apr 14;11(4):230. (PMID: 32286266)
Mol Cell Oncol. 2014 Jul 28;1(1):e29912. (PMID: 27308319)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1420-D1430. (PMID: 33179754)
CA Cancer J Clin. 2019 Jul;69(4):280-304. (PMID: 31099893)
J Cell Physiol. 2019 Apr;234(4):3730-3743. (PMID: 30171601)
Cell Death Differ. 2005 Nov;12 Suppl 2:1473-7. (PMID: 16247493)
Theranostics. 2020 Jun 12;10(17):7545-7560. (PMID: 32685004)
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498. (PMID: 23830918)
Crit Rev Oncog. 2016;21(3-4):155-168. (PMID: 27915969)
Gynecol Oncol. 2005 Dec;99(3):656-63. (PMID: 16112717)
Crit Rev Oncol Hematol. 2019 Aug;140:17-27. (PMID: 31154235)
Br J Cancer. 1995 Oct;72(4):883-8. (PMID: 7547235)
Int J Mol Sci. 2018 Mar 19;19(3):. (PMID: 29562686)
Br J Cancer. 2020 Sep;123(7):1154-1163. (PMID: 32632148)
Cancer Cell. 2009 Dec 8;16(6):521-32. (PMID: 19962670)
J Ginseng Res. 2021 Jan;45(1):134-148. (PMID: 33437165)
Front Oncol. 2021 Mar 29;11:626577. (PMID: 33854965)
Oncogene. 2017 Jul 6;36(27):3797-3806. (PMID: 28218905)
Bioinformatics. 2018 Jul 1;34(13):i555-i564. (PMID: 29950010)
Bioinformatics. 2010 Jun 15;26(12):1572-3. (PMID: 20427518)
Cell Death Differ. 2022 Feb;29(2):323-336. (PMID: 34462553)
Int J Mol Sci. 2021 Jun 18;22(12):. (PMID: 34207103)
Mol Cancer Res. 2020 Jul;18(7):1088-1098. (PMID: 32198139)
Cell Rep. 2021 Apr 13;35(2):108978. (PMID: 33852846)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Oncotarget. 2016 Jan 26;7(4):3832-46. (PMID: 26716645)
Cells. 2019 Dec 18;9(1):. (PMID: 31861382)
World J Biol Chem. 2012 Aug 26;3(8):167-74. (PMID: 22937213)
Oncogene. 2018 Nov;37(46):6025-6040. (PMID: 29995871)
Indian J Dermatol. 2016 May-Jun;61(3):251-60. (PMID: 27293244)
Cell Rep. 2017 Jan 3;18(1):248-262. (PMID: 28052254)
BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831)
Cancer Res. 2022 Mar 15;82(6):1038-1054. (PMID: 34654724)
J Pathol. 2012 Jan;226(2):380-93. (PMID: 21953325)
Gynecol Oncol. 2019 Jan;152(1):194-201. (PMID: 30297273)
Cancers (Basel). 2019 Dec 19;12(1):. (PMID: 31861681)
Br J Cancer. 2017 Oct 10;117(8):1192-1201. (PMID: 28817834)
Cell Death Differ. 2013 Mar;20(3):443-55. (PMID: 23175185)
BMC Cancer. 2010 Apr 13;10:139. (PMID: 20388222)
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. (PMID: 27743768)
Oncogenesis. 2018 Nov 26;7(11):92. (PMID: 30478317)

2020J011220 Natural Science Foundation of Fujian Province; 3502Z20209002 Key Medical and Health Projects in Xiamen; 81772893 National Natural Science Foundation of China

Date Created: 20240118 Date Completed: 20240122 Latest Revision: 20240122

20240122

PMC10796408

10.1038/s41598-024-52117-0

38238592